Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil (FTD/TPI) to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2023 Results of sub group analysis assessing effect of Trifluridine/tipiracil in extensively pretreated metastatic colorectal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
25 May 2023 According to a Servier media release, an evaluation of prognostic subgroups of the TALLISUR study will be presented at 2023 ASCO annual meeting.
08 Jun 2021 Interim results (n=194) assessing effect of FTD/TPI on health-related quality of life (HRQoL)in patients with pre-treated metastatic colorectal cancer (TALLISUR study) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com